REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
11

My Experience with Zepbound After 3 Months

Petra Harrison·21 days ago
Three months of Zepbound in the books. Here is my honest assessment without the hype. What improved: - Recovery between training sessions (significant) - Sleep quality, particularly deep sleep duration - General sense of wellbeing and mood stability - Skin quality — not something I expected but multiple people commented on it What did not change much: - Strength levels (modest improvement at best) - Body weight (stayed within 2 lbs of starting weight) - Appetite (no noticeable change either direction) Timeline of effects: the first 2-3 weeks were essentially a placebo-free zone. I felt nothing and wondered if I was wasting my time. Week 3-4 is when the sleep improvements kicked in. By week 6, recovery benefits were clear. Weeks 8-12 felt like a plateau but in a good way — consistent benefits without escalation. Would I run it again? Yes, after a break. I think cycling is important both for maintaining sensitivity and for verifying that the benefits were actually from Zepbound and not just other lifestyle factors.

Comments (7)

Cameron BakerDEMO·21 days ago

The honest assessment without hype is refreshing. The fact that strength did not change much but recovery improved significantly suggests the GH-related benefits are more about tissue repair than raw hypertrophy. That aligns with the literature.

0
Lennox ChenDEMO·21 days ago

Solid protocol. One suggestion: consider adding HRV tracking if you are not already. It has been the most objective and responsive metric for me during my Zepbound protocol. Changes in HRV preceded subjective improvements by about a week, which gave me early confidence the protocol was working.

2
Darcy HartDEMO·21 days ago

Your point about consistency being more important than optimization really resonates. I wasted weeks early in my Zepbound journey tweaking doses and timing when I should have just picked a reasonable protocol and stuck with it. The best results came when I stopped overthinking and just stayed consistent.

3
Sage CampbellDEMO·20 days ago

This is a great discussion about Zepbound. I want to add that I found morning dosing on an empty stomach gave me noticeably better results than evening dosing. Tried both for 4 weeks each. The difference was subtle but consistent across my tracking metrics.

4
Sasha CortlandDEMO·20 days ago

Your timeline of effects is almost identical to mine. Weeks 1-3 nothing, then sleep improvements, then recovery. I wonder if the sleep improvement is actually driving the recovery benefits rather than a direct tissue repair effect.

0
Dale BanksDEMO·19 days ago

The cycling approach is smart. Receptor desensitization is a real concern with prolonged use. How long of a break are you planning? I have seen recommendations ranging from 4 weeks to equal time off as on.

0
Hayden ArcherDEMO·18 days ago

Skin quality improvement being unexpected is interesting - multiple people report this. Could be related to increased collagen synthesis from elevated GH. It is one of those benefits that takes people by surprise but makes biological sense.

0

Sign in to comment.